| Q40668927 | A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial |
| Q99616765 | A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma |
| Q83519492 | Atypical diaphyseal femoral fractures--new aspects |
| Q33715141 | Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays |
| Q36196602 | Bone structural components regulating sites of tumor metastasis |
| Q38364893 | Bone's Material Constituents and their Contribution to Bone Strength in Health, Disease, and Treatment. |
| Q37905720 | Contribution of bone tissue modulus to breast cancer metastasis to bone |
| Q34758541 | Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs |
| Q38507547 | Emerging role of alpha-lipoic acid in the prevention and treatment of bone loss |
| Q37792889 | Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review |
| Q34936324 | Nephrolithiasis-associated bone disease: pathogenesis and treatment options |
| Q35036461 | Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures |
| Q37798836 | Oral salmon calcitonin--pharmacology in osteoporosis |
| Q37414127 | Proximal femoral fractures: Principles of management and review of literature |
| Q51139907 | Stress fracture of the ulna associated with bisphosphonate therapy and use of walking aid. |
| Q35229889 | Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996–2007 |
| Q50671913 | Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series. |
| Q82589085 | Update in new medications for primary care |
| Q34877539 | Use of bisphosphonates and reduced risk of colorectal cancer |
| Q37800181 | Use of bisphosphonates in the management of postmenopausal osteoporosis |
| Q55452474 | Les bisphosphonates dans le traitement de l’ostéoporose: Bienfaits attendus, torts potentiels et congés thérapeutiques. |